Drug Innovation
Commentary
The GLP-1 Shortage Is Over. Mass-Market Compounding Should Be, Too
The U.S. Food and Drug Administration’s effort to rein in mass-market copies of blockbuster GLP-1 drugs just survived a major legal challenge. Last month, the U.S. Court of Appeals for the Fifth Circuit upheld the agency’s determination that the shortage of semaglutide—the active ingredient in Ozempic and Wegovy—is over. In ...
Commentary
The first mRNA flu vaccine may be just the beginning
Flu season is coming. And for the first time, Americans will have an mRNA vaccine to help fight it. Last month, the Food and Drug Administration approved Moderna’s mFLUSIVA for adults 50 and older. In a large Phase 3 trial, the vaccine was almost 27% more effective than a standard ...
Commentary
CMS Undermining Next Generation of Medicines
Some of the biggest advances in medicine don’t come from discovering entirely new drugs. They come from making existing ones easier to take, faster to administer, safer, and more effective. A new proposal from the Centers for Medicare and Medicaid Services could make those improvements far less common. The agency ...
Drug Innovation
California Supreme Court Decision Protects Future Medical Innovation
The Pacific Research Institute – the non-partisan, California-based, free-market think tank – today hailed a landmark California Supreme Court decision protecting future medical innovation. The ruling in the Gilead Tenofir Cases overturns a lower court decision that threatened to expose pharmaceutical innovators to sweeping new liability for decisions about the ...
Biosimilars
PBM’s Drug Cut Exceeds the Total Cost of Medicines In Most Other Countries
Another fundamental problem is these comparisons rely on U.S. medicines’ gross (or list) price. But list prices do not account for the complex U.S. drug supply chain, where manufacturers receive only a portion of the gross price and intermediaries, such as pharmacy benefit managers (PBMs), receive a disproportionate share. As ...
Drug Innovation
Unauthorized GLP-1 Knockoffs Risk Patient Safety and Future Innovation, New PRI Brief Warns
As federal regulators intensify enforcement against companies selling unauthorized knockoffs of blockbuster weight-loss drugs, a new Pacific Research Institute brief warns that the booming GLP-1 knockoff market is creating patient safety risks while undermining future breakthrough medicines. “GLP-1s are among the most promising medical breakthroughs in decades, helping patients struggling ...
Commentary
Americans Get Medicines First – Why?
Americans hear a lot these days about how Europe has healthcare all figured out. Progressives love pointing to countries like Britain, France, and Canada as models America should follow — especially when it comes to prescription drug prices. What they rarely mention is the price those countries pay for government-controlled ...
Commentary
Read the latest on drug innovation from Sally Pipes
Big Medical Breakthroughs Start With Small Gains
That may not sound like much. For someone facing a terminal diagnosis, what difference does a few extra months really make, especially if the drugs that enable them cost tens of thousands of dollars, as so many cancer drugs do? That question misses the point. In medicine, the most important ...
Commentary
A lawsuit that may kill tomorrow’s cures
On Wednesday, May 6, the California Supreme Court will hear a case that could upend the economics of medical innovation. Roughly 24,000 plaintiffs are suing pharmaceutical company Gilead over one of its HIV drugs. They do not claim that the drug failed to work, nor that it was defectively manufactured, ...
Commentary
Can You Sue A Drug Company For Not Inventing Faster?
This week, the California Supreme Court is set to hear a case that could have far-reaching consequences for medical science. At issue is Gilead Sciences’ HIV treatment tenofovir disoproxil fumarate, or TDF. Tens of thousands of plaintiffs allege they suffered side effects while taking the drug. They are not arguing ...
The GLP-1 Shortage Is Over. Mass-Market Compounding Should Be, Too
The U.S. Food and Drug Administration’s effort to rein in mass-market copies of blockbuster GLP-1 drugs just survived a major legal challenge. Last month, the U.S. Court of Appeals for the Fifth Circuit upheld the agency’s determination that the shortage of semaglutide—the active ingredient in Ozempic and Wegovy—is over. In ...
The first mRNA flu vaccine may be just the beginning
Flu season is coming. And for the first time, Americans will have an mRNA vaccine to help fight it. Last month, the Food and Drug Administration approved Moderna’s mFLUSIVA for adults 50 and older. In a large Phase 3 trial, the vaccine was almost 27% more effective than a standard ...
CMS Undermining Next Generation of Medicines
Some of the biggest advances in medicine don’t come from discovering entirely new drugs. They come from making existing ones easier to take, faster to administer, safer, and more effective. A new proposal from the Centers for Medicare and Medicaid Services could make those improvements far less common. The agency ...
California Supreme Court Decision Protects Future Medical Innovation
The Pacific Research Institute – the non-partisan, California-based, free-market think tank – today hailed a landmark California Supreme Court decision protecting future medical innovation. The ruling in the Gilead Tenofir Cases overturns a lower court decision that threatened to expose pharmaceutical innovators to sweeping new liability for decisions about the ...
PBM’s Drug Cut Exceeds the Total Cost of Medicines In Most Other Countries
Another fundamental problem is these comparisons rely on U.S. medicines’ gross (or list) price. But list prices do not account for the complex U.S. drug supply chain, where manufacturers receive only a portion of the gross price and intermediaries, such as pharmacy benefit managers (PBMs), receive a disproportionate share. As ...
Unauthorized GLP-1 Knockoffs Risk Patient Safety and Future Innovation, New PRI Brief Warns
As federal regulators intensify enforcement against companies selling unauthorized knockoffs of blockbuster weight-loss drugs, a new Pacific Research Institute brief warns that the booming GLP-1 knockoff market is creating patient safety risks while undermining future breakthrough medicines. “GLP-1s are among the most promising medical breakthroughs in decades, helping patients struggling ...
Americans Get Medicines First – Why?
Americans hear a lot these days about how Europe has healthcare all figured out. Progressives love pointing to countries like Britain, France, and Canada as models America should follow — especially when it comes to prescription drug prices. What they rarely mention is the price those countries pay for government-controlled ...
Read the latest on drug innovation from Sally Pipes
Big Medical Breakthroughs Start With Small Gains
That may not sound like much. For someone facing a terminal diagnosis, what difference does a few extra months really make, especially if the drugs that enable them cost tens of thousands of dollars, as so many cancer drugs do? That question misses the point. In medicine, the most important ...
A lawsuit that may kill tomorrow’s cures
On Wednesday, May 6, the California Supreme Court will hear a case that could upend the economics of medical innovation. Roughly 24,000 plaintiffs are suing pharmaceutical company Gilead over one of its HIV drugs. They do not claim that the drug failed to work, nor that it was defectively manufactured, ...
Can You Sue A Drug Company For Not Inventing Faster?
This week, the California Supreme Court is set to hear a case that could have far-reaching consequences for medical science. At issue is Gilead Sciences’ HIV treatment tenofovir disoproxil fumarate, or TDF. Tens of thousands of plaintiffs allege they suffered side effects while taking the drug. They are not arguing ...